Is LDL-C passed its prime? The emerging role of Non-HDL, LDL-P, and ApoB in CHD risk assessment

被引：17
|
作者：
Davidson, Michael H. [1 ]
机构：
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60654 USA
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2008年 / 28卷 / 09期
关键词：
D O I：
10.1161/ATVBAHA.108.172718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1582 / 1583
页数：2
相关论文
共 50 条
  • [21] ApoB, non-HDL-C, and LDL-C Are More Prominent in Retinal Artery Occlusion Compared to Retinal Vein Occlusion
    Chen, Ting
    Li, Ying
    Wang, Yuedan
    Li, Xuejie
    Wan, Yuwei
    Xiao, Xuan
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (05) : 534 - 540
  • [22] Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
    Yun, Yeo-Min
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (03) : 221 - 222
  • [23] DOES LOW HDL-C INCREASE CHD RISK WHEN TG & LDL-C ARE NORMAL? THE FRAMINGHAM OFSPRING STUDY
    Miller, Michael
    Kim, Yeunjung
    Havas, Stephen
    Kwiterovich, Peter
    Fazio, Sergio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1286 - A1286
  • [24] EZETIMIBE/SIMVASTATIN (E/S) AND ATORVASTATIN (A) TREATMENT MODIFY APOB, LDL-C, AND NON-HDL-C CORRELATIONS IN METABOLIC SYNDROME (MS) PATIENTS AT MODERATELY HIGH RISK(MHR)/HIGH RISK(HR) FOR CHD
    Ballantyne, C.
    Grundy, S.
    Hsueh, W.
    Parving, H.
    Robinson, J.
    Rosen, J.
    Lin, J.
    Lowe, R.
    Shah, A.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [25] CORRELATION OF NON-HDL-C AND LDL-C WITH APOB DURING LIPID-LOWERING THERAPY IN PATIENTS WITH COMBINED HYPERLIPIDEMIA (HL)
    Grundy, S.
    Vega, G.
    Tomassini, J.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [26] Age, Abdominal Obesity, and Baseline hsCRP Are Associated with LDL-C, Non-HDL-C and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High CHD Risk
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa A.
    Rosen, Jeffrey B.
    Lin, Jianxin
    Shah, Arvind K.
    Tomassini, Joanne E.
    Lowe, Robert S.
    Tershakovec, Andrew M.
    DIABETES, 2011, 60 : A188 - A188
  • [27] ApoB is superior to LDL-C or non-HDL-C as a lipid marker for predicting the presence and severity of atherosclerosis in female patients with myocardial infarction
    Zhang, Hui-Wen
    Zhao, Xi
    Zhang, Yan
    Li, Sha
    Zhu, Cheng-Gang
    Guo, Yuan-Lin
    Wu, Na-Qiong
    Gao, Ying
    Qing, Ping
    Sun, Jing
    Liu, Geng
    Dong, Qian
    Li, Jian-Jun
    HELLENIC JOURNAL OF CARDIOLOGY, 2017, 58 (03) : 223 - 225
  • [28] The non-HDL-C to APOB ratio as a predictor of inaccurate LDL-C measurement in patients with chronic intrahepatic cholestasis and jaundice: a retrospective study
    Cheng, Yongjiang
    Ye, Jingyan
    Huang, Junyuan
    Wang, Yang
    PEERJ, 2024, 12
  • [29] Utility of Non-hdl-c and Apob Targets at Progressively Lower Ldl-c Down to Levels Less Than 40 Mg/dl
    Sathiyakumar, Vasanth
    Park, Jihwan
    Sajja, Aparna
    Guallar, Eliseo
    Lazo, Mariana
    Jones, Steven R.
    Martin, Seth S.
    CIRCULATION, 2019, 140
  • [30] Relations of Change in Plasma Levels of LDL-C, Non-HDL-C and apoB With Risk Reduction From Statin Therapy: A Meta-Analysis of Randomized Trials
    Thanassoulis, George
    Williams, Ken
    Ye, Keying
    Brook, Robert
    Couture, Patrick
    Lawler, Patrick R.
    de Graaf, Jacqueline
    Furberg, Curt D.
    Sniderman, Allan
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (02): : e000759
12345